The Binding Interface between Human APOBEC3F and HIV-1 Vif Elucidated by Genetic and Computational Approaches

Cell Reports

Volumn 13, Issue 9, 2015, Pages 1781-1788

  Richards, Christopher ^a,b,c   Albin, John S ^a,b,c,e   Demir, Özlem ^d   Shaban, Nadine M ^a,b,c   Luengas, Elizabeth M ^a,b,c   Land, Allison M ^a,b,c,f   Anderson, Brett D ^a,b,c   Holten, John R ^a,b,c,g   Anderson, John S ^a,b,c,h   Harki, Daniel A ^a,c   Amaro, Rommie E ^d   Harris, Reuben S ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MINNESOTA STATE UNIVERSITY MANKATO   (United States)

^g TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Des Moines University College of Osteopathic Medicine   (United States)

Author keywords

APOBEC3F; APOBEC3F Vif interface; HIV 1; Pathogen host interaction; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; VIF PROTEIN; APOBEC3F PROTEIN, HUMAN; CYTOSINE DEAMINASE; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; EVOLUTIONARY ADAPTATION; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN PROTEIN INTERACTION; STATIC ELECTRICITY; STRUCTURAL MODEL; VALIDATION STUDY; VIRUS INFECTIVITY; VIRUS REPLICATION; AMINO ACID SEQUENCE; BINDING SITE; CELL LINE; CHEMISTRY; GENETICS; HUMAN; INNATE IMMUNITY; METABOLISM; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS;

AMINO ACID SEQUENCE; BINDING SITES; CELL LINE; CYTOSINE DEAMINASE; HIV-1; HUMANS; IMMUNITY, INNATE; MOLECULAR DYNAMICS SIMULATION; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; STATIC ELECTRICITY; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84949024202     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.10.067     Document Type: Article

References (36)

1. Albin J.S., Haché G., Hultquist J.F., Brown W.L., Harris R.S. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J. Virol. 2010, 84:10209-10219.
2. Albin J.S., LaRue R.S., Weaver J.A., Brown W.L., Shindo K., Harjes E., Matsuo H., Harris R.S. A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 2010, 285:40785-40792.
3. Anderson B.D., Harris R.S. Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-β/RUNX axis. Sci. Adv. 2015, 1:e1500296.
4. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 2004, 14:1392-1396.
5. Bohn M.F., Shandilya S.M., Albin J.S., Kouno T., Anderson B.D., McDougle R.M., Carpenter M.A., Rathore A., Evans L., Davis A.N., et al. Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. Structure 2013, 21:1042-1050.
6. Desimmie B.A., Delviks-Frankenberrry K.A., Burdick R.C., Qi D., Izumi T., Pathak V.K. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J. Mol. Biol. 2014, 426:1220-1245.
7. Desrosiers R.C., Lifson J.D., Gibbs J.S., Czajak S.C., Howe A.Y., Arthur L.O., Johnson R.P. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 1998, 72:1431-1437.
8. Farrow M.A., Somasundaran M., Zhang C., Gabuzda D., Sullivan J.L., Greenough T.C. Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation. AIDS Res. Hum. Retroviruses 2005, 21:565-574.
9. Guo Y., Dong L., Qiu X., Wang Y., Zhang B., Liu H., Yu Y., Zang Y., Yang M., Huang Z. Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif. Nature 2014, 505:229-233.
10. Haché G., Liddament M.T., Harris R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 2005, 280:10920-10924.
11. Haché G., Shindo K., Albin J.S., Harris R.S. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 2008, 18:819-824.
12. Haché G., Abbink T.E., Berkhout B., Harris R.S. Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J. Virol. 2009, 83:5956-5960.
13. Harris R.S., Dudley J.P. APOBECs and virus restriction. Virology 2015, 479-480:131-145.
14. Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L., Brown W.L., Harris R.S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011, 85:11220-11234.
15. Kitamura S., Ode H., Nakashima M., Imahashi M., Naganawa Y., Kurosawa T., Yokomaku Y., Yamane T., Watanabe N., Suzuki A., et al. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 2012, 19:1005-1010.
16. Kouno T., Luengas E.M., Shigematsu M., Shandilya S.M., Zhang J., Chen L., Hara M., Schiffer C.A., Harris R.S., Matsuo H. Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G. Nat. Struct. Mol. Biol. 2015, 22:485-491.
17. Krisko J.F., Martinez-Torres F., Foster J.L., Garcia J.V. HIV restriction by APOBEC3 in humanized mice. PLoS Pathog. 2013, 9:e1003242.
18. Land A.M., Shaban N.M., Evans L., Hultquist J.F., Albin J.S., Harris R.S. APOBEC3F determinants of HIV-1 Vif sensitivity. J. Virol. 2014, 88:12923-12927.
19. Liddament M.T., Brown W.L., Schumacher A.J., Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 2004, 14:1385-1391.
20. Ooms M., Brayton B., Letko M., Maio S.M., Pilcher C.D., Hecht F.M., Barbour J.D., Simon V. HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe 2013, 14:411-421.
21. Rangel H.R., Garzaro D., Rodríguez A.K., Ramírez A.H., Ameli G., Del Rosario Gutiérrez C., Pujol F.H. Deletion, insertion and stop codon mutations in vif genes of HIV-1 infecting slow progressor patients. J. Infect. Dev. Ctries. 2009, 3:531-538.
22. Refsland E.W., Hultquist J.F., Harris R.S. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 2012, 8:e1002800.
23. Refsland E.W., Hultquist J.F., Luengas E.M., Ikeda T., Shaban N.M., Law E.K., Brown W.L., Reilly C., Emerman M., Harris R.S. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet. 2014, 10:e1004761.
24. Russell R.A., Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 2007, 81:8201-8210.
25. Russell R.A., Smith J., Barr R., Bhattacharyya D., Pathak V.K. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 2009, 83:1992-2003.
26. Sato K., Takeuchi J.S., Misawa N., Izumi T., Kobayashi T., Kimura Y., Iwami S., Takaori-Kondo A., Hu W.S., Aihara K., et al. APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog. 2014, 10:e1004453.
27. Schmitt K., Hill M.S., Liu Z., Ruiz A., Culley N., Pinson D.M., Stephens E.B. Comparison of the replication and persistence of simian-human immunodeficiency viruses expressing Vif proteins with mutation of the SLQYLA or HCCH domains in macaques. Virology 2010, 404:187-203.
28. Schröfelbauer B., Senger T., Manning G., Landau N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 2006, 80:5984-5991.
29. Simon V., Zennou V., Murray D., Huang Y., Ho D.D., Bieniasz P.D. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 2005, 1:e6.
30. Siu K.K., Sultana A., Azimi F.C., Lee J.E. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F. Nat. Commun. 2013, 4:2593.
31. Smith J.L., Pathak V.K. Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 2010, 84:12599-12608.
32. Van Valen L. A new evolutionary law. Evol. Theory 1973, 1:1-30.
33. Virgen C.A., Hatziioannou T. Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins. J. Virol. 2007, 81:13932-13937.
34. Wiegand H.L., Doehle B.P., Bogerd H.P., Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 2004, 23:2451-2458.
35. Zennou V., Bieniasz P.D. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 2006, 349:31-40.
36. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 2004, 78:6073-6076.